Volitionrx Ltd (VNRX)
Official siteHEALTHCARE • MEDICAL DEVICES • AMEX
Market Cap: $8.30M
Last updated: Nov 17, 2026 at 11:04 AM ET
Volitionrx Ltd (VNRX) Earnings: Report Dates and Results
Volitionrx (VNRX) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Volitionrx reported EPS of -$0.20, above the -$0.35 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VNRX has an expected report date of Mar 29, 2027.
VNRX Earnings Call
The latest VNRX earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 40 quarters below that had an estimate, VNRX beat 20, missed 14 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $1.61M, up 156.7% from $627277 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.20 | -$0.35 | N/A | +42.86% | Beat | N/A | 1 | 0 up, 0 down | Nov 12, 2026 | $1.61M |
| Jun 30, 2026 | -$0.78 | -$0.68 | N/A | -14.71% | Miss | N/A | 1 | 0 up, 1 down | Aug 13, 2026 | $398657 |
| Mar 31, 2026 | -$0.97 | -$0.73 | -$0.80 - -$0.60 | -32.88% | Miss | N/A | 3 | 1 up, 0 down | May 14, 2026 | $985076 |
| Dec 31, 2025 | -$0.05 | -$0.05 | N/A | +2.78% | Beat | N/A | 5 | 0 up, 0 down | Mar 31, 2026 | $447034 |
| Sep 30, 2025 | -$1.06 | -$1.04 | -$1.40 - -$0.80 | -1.92% | Miss | N/A | 5 | 0 up, 2 down | Nov 13, 2025 | $627277 |
| Jun 30, 2025 | -$1.31 | -$1.00 | -$1.20 - -$0.80 | -31.00% | Miss | N/A | 6 | 0 up, 1 down | Aug 14, 2025 | $406688 |
| Mar 31, 2025 | -$0.06 | -$0.06 | -$0.06 - -$0.02 | 0.00% | In line | N/A | 4 | 1 up, 0 down | May 15, 2025 | $246385 |
| Dec 31, 2024 | -$1.20 | -$1.07 | -$1.20 - -$0.80 | -12.15% | Miss | N/A | 3 | 0 up, 0 down | Mar 31, 2025 | $194595 |
| Sep 30, 2024 | -$1.40 | -$1.30 | -$1.60 - -$1.00 | -7.69% | Miss | N/A | 5 | 2 up, 0 down | Nov 14, 2024 | $474522 |
| Jun 30, 2024 | -$1.60 | -$1.85 | -$2.20 - -$1.80 | +13.51% | Beat | N/A | 4 | 0 up, 0 down | Aug 14, 2024 | $395797 |
| Mar 31, 2024 | -$2.00 | -$2.15 | -$2.40 - -$2.00 | +6.98% | Beat | N/A | 4 | 0 up, 0 down | May 13, 2024 | $168597 |
| Dec 31, 2023 | -$0.11 | -$0.11 | -$0.11 - -$0.10 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Mar 26, 2024 | $243973 |
| Sep 30, 2023 | -$2.14 | -$2.47 | -$3.00 - -$2.40 | +13.36% | Beat | N/A | 5 | 0 up, 0 down | Nov 14, 2023 | $165211 |
| Jun 30, 2023 | -$2.80 | -$2.87 | -$3.20 - -$2.60 | +2.44% | Beat | N/A | 4 | 0 up, 0 down | Aug 15, 2023 | $216310 |
| Mar 31, 2023 | -$3.00 | -$2.70 | -$3.00 - -$2.60 | -11.11% | Miss | N/A | 3 | 0 up, 0 down | May 11, 2023 | $149808 |
| Dec 31, 2022 | -$0.13 | -$0.15 | -$0.15 - -$0.14 | +13.33% | Beat | N/A | 5 | 0 up, 0 down | Mar 15, 2023 | $119715 |
| Sep 30, 2022 | -$2.80 | -$2.93 | -$3.20 - -$2.80 | +4.44% | Beat | N/A | 5 | 0 up, 0 down | Nov 14, 2022 | $32714 |
| Jun 30, 2022 | -$2.80 | -$2.87 | N/A | +2.44% | Beat | N/A | N/A | 0 up, 0 down | Aug 10, 2022 | $39752 |
| Mar 31, 2022 | -$2.80 | $0.90 | -$0.80 - $1.00 | -411.11% | Miss | N/A | 4 | 0 up, 0 down | May 11, 2022 | $114211 |
| Dec 31, 2021 | -$0.15 | -$0.14 | -$0.15 - -$0.11 | -7.14% | Miss | N/A | 4 | N/A | Mar 30, 2022 | $14240 |
| Sep 30, 2021 | -$2.60 | -$2.07 | -$2.60 - -$2.00 | -25.60% | Miss | N/A | 5 | N/A | Nov 10, 2021 | $25483 |
| Jun 30, 2021 | -$2.08 | -$2.33 | -$2.60 - -$2.00 | +10.73% | Beat | N/A | 5 | N/A | Aug 11, 2021 | $24782 |
| Mar 31, 2021 | -$2.40 | -$2.27 | -$2.40 - -$2.20 | -5.73% | Miss | N/A | 3 | N/A | May 11, 2021 | $25530 |
| Dec 31, 2020 | -$0.11 | -$0.10 | -$0.10 - -$0.10 | -10.00% | Miss | N/A | 3 | N/A | Mar 22, 2021 | $20553 |
| Sep 30, 2020 | -$1.93 | -$2.20 | -$2.40 - -$2.20 | +12.27% | Beat | N/A | 4 | N/A | Nov 12, 2020 | $575 |
| Jun 30, 2020 | -$2.36 | -$2.45 | -$3.00 - -$2.00 | +3.67% | Beat | N/A | 5 | N/A | Aug 13, 2020 | $5194 |
| Mar 31, 2020 | -$2.80 | -$1.93 | N/A | -45.08% | Miss | N/A | 2 | N/A | May 7, 2020 | $544 |
| Dec 31, 2019 | -$1.60 | -$2.20 | -$2.20 - -$2.00 | +27.27% | Beat | N/A | 2 | N/A | Feb 20, 2020 | N/A |
| Sep 30, 2019 | -$2.00 | -$2.10 | -$2.20 - -$2.00 | +4.76% | Beat | N/A | 3 | N/A | Nov 12, 2019 | $17096 |
| Jun 30, 2019 | -$2.20 | -$2.27 | -$2.40 - -$2.20 | +3.08% | Beat | N/A | 4 | N/A | Aug 12, 2019 | N/A |
| Mar 31, 2019 | -$2.40 | -$2.40 | -$2.60 - -$2.20 | 0.00% | In line | N/A | 3 | N/A | May 8, 2019 | N/A |
| Dec 31, 2018 | -$0.11 | -$0.13 | -$0.15 - -$0.12 | +15.38% | Beat | N/A | 3 | N/A | Mar 13, 2019 | N/A |
| Sep 30, 2018 | -$2.80 | -$2.80 | -$3.20 - -$2.60 | 0.00% | In line | N/A | 3 | N/A | Nov 7, 2018 | N/A |
| Jun 30, 2018 | -$3.00 | -$3.00 | -$3.20 - -$2.60 | 0.00% | In line | N/A | 4 | N/A | Aug 13, 2018 | N/A |
| Mar 31, 2018 | -$3.40 | -$3.20 | -$3.20 - -$3.20 | -6.25% | Miss | N/A | 1 | N/A | May 10, 2018 | N/A |
| Dec 31, 2017 | -$0.15 | -$0.16 | -$0.17 - -$0.15 | +6.25% | Beat | N/A | 3 | N/A | Mar 1, 2018 | N/A |
| Sep 30, 2017 | -$3.00 | -$3.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 9, 2017 | N/A |
| Jun 30, 2017 | -$2.60 | -$2.80 | N/A | +7.14% | Beat | N/A | N/A | N/A | Aug 9, 2017 | N/A |
| Mar 31, 2017 | -$2.60 | -$2.75 | N/A | +5.45% | Beat | N/A | N/A | N/A | May 11, 2017 | N/A |
| Dec 31, 2016 | -$0.12 | -$0.13 | N/A | +7.69% | Beat | N/A | N/A | N/A | Mar 10, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.48, after -$6.20 the year before. It was -$8.32 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.48 | N/A |
| Dec 31, 2024 | -$6.20 | N/A |
| Dec 31, 2023 | -$8.05 | N/A |
| Dec 31, 2022 | -$8.53 | N/A |
| Dec 31, 2021 | -$7.23 | N/A |
| Dec 31, 2020 | -$7.20 | N/A |
| Dec 31, 2019 | -$8.20 | N/A |
| Dec 31, 2018 | -$9.31 | N/A |
| Dec 31, 2017 | -$8.35 | N/A |
| Dec 31, 2016 | -$8.32 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 5,700 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 5,699 | 9 | |
| 2025Q4 | Dec 31, 2025 | 6,417 | 10 | |
| 2025Q3 | Sep 30, 2025 | 6,036 | 9 | |
| 2025Q2 | Jun 30, 2025 | 6,249 | 9 | |
| 2025Q1 | Mar 31, 2025 | 4,670 | 6 | |
| 2024Q3 | Sep 30, 2024 | 7,943 | 10 | |
| 2024Q2 | Jun 30, 2024 | 4,623 | 11 |
2026Q1 Earnings Call
Opening remarks
Louise Batchelor Day Group Chief Marketing and Communications Officer Thank you, and welcome, everyone, to today's earnings conference call for VolitionRx Limited. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements made during the course of this call. Terig Hughes, Group Chief Financial Officer, will open the call providing a financial report before handing over to Cameron Reynolds, Group Chief Executive Officer, who will provide a summary of recent key achievements and upcoming milestones. We will then open the conference call to a question-and-answer session. And with that, I'll turn the call over to Terig.
Terig Hughes Group Chief Financial Officer Thanks very much, Lou, and hello, everyone. I'm delighted to provide a financial report for the first quarter ending 31st of March 2026. From a revenue perspective, we recorded approximately $1 million in the first quarter compared to approximately $0.2 million in the same period of 2025. This increase was primarily driven by a $0.7 million increase in deferred revenue recognition related to our Nu.Q Vet agreement with Heska, the result of a periodic review and consistent with our accounting policies. As we have stated previously, at this stage of commercialization, revenues remain fairly lumpy and difficult to predict from one quarter to the next. And so while we remain confident of continuing to see solid growth year-over-year, we will not be providing revenue guidance for 2026 at this point in time. From an expenditure perspective, the operating expenses for the quarter were $6.3 million compared to $5.8 million in the same period last year. This increase partly reflected severance costs related to cost reduction actions, which will result in future savings as well as higher R&D costs related to work on our Capture-Seq and completion of certain lung cancer studies. As we reported in the recent 10-K, looking at the trend over the last two years, we now operate at significantly lower levels of expenditure.
Frequently Asked Questions About VNRX
When is Volitionrx's next earnings date?
Volitionrx's next earnings report is expected for Mar 29, 2027.
Did VNRX beat earnings estimates last quarter?
Yes. Volitionrx reported EPS of -$0.20 for the quarter ended Sep 30, 2026, above the -$0.35 estimate, a 42.86% surprise.
What EPS do analysts expect from VNRX next quarter?
The consensus EPS estimate for Volitionrx for the quarter ending Dec 31, 2026 is -$0.29 from 7 analysts, with estimates from -$0.37 to -$0.20.
How often does VNRX beat earnings estimates?
Volitionrx beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -5.88%.
VNRX pages: Overview, Earnings, Forecast, Financials, Competitors